The expression of TRAIL-R1 and TRAIL-R2 is reported to be high in AML patients, and there has been evidence which shows high co-TRAIL-R3 expression linked to poor overall survival of the patients (111). This evidence concerns the gene TNFRSF10A and acute myeloid leukemia.